Drugs / CTL 19
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04180059 | Feb 2020 → Jul 2027 expected | hematopoietic and lymphoid system neoplasm | Nantes University Hospital | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTL 19 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04180059 ↗ |
| Action | Deplete | “have been demonstrated to be able to kill HLA-DPB1\*04:01 positive leukemic cells” NCT04180059 ↗ |
| Modality | Cell therapy | “T cell clone” NCT04180059 ↗ |
| Route | Intravenous | “inject iv escalating dose” NCT04180059 ↗ |
| Target | HLA-DPB1 | “clone recognizing HLA-DPB1\*04:01” NCT04180059 ↗ |